SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude climbs amid reported tanker and energy-infrastructure attacks and fears of supply disruption around the Strait of Hormuz, with Ukraines strikes on Russian oil facilities adding to supply concerns. Traders are divided between those betting on further gains from persistent risks and those expecting a pullback if tensions ease, while some warn the rally looks crowded or overextended.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Discussion centers on GameStops warrants nearing their stated expiration: with shares below the exercise price, traders debate whether they will expire worthless or whether Ryan Cohen will extend or otherwise change the terms. Some view non-exercise as avoiding dilution, while warrant holders and skeptical shareholders worry about losses and criticize the lack of a company catalyst; attention also remains on whether shares can hold technical support.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Hot inflation readings and rising-yield concerns have pressured rate-sensitive small caps, with traders highlighting IWMs breakdown and heavy demand for puts. The community is split between expecting further downside and looking for an oversold bounce near support.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led relief rally after a sharp AI-related selloff has put QQQ in focus, with traders debating whether the volatile rebound signals recovery or is a temporary bounce. Upcoming megacap earnings are a key test, while concerns about AI infrastructure spending and weak market breadth sustain bearish views.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is drawing attention amid a semiconductor and AI-stock selloff, with traders citing concerns about AI infrastructure financing and Hock Tans warnings about capital constraints, as well as backlash to his casino remarks. The 10-year NTT DOCOMO VMware agreement is seen as positive by some, but debate remains split between bearish concerns about AVGOs weak performance and dip-buying optimism.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is drawing attention ahead of its earnings report, with traders focused on whether AI- and memory-driven equipment demand will support strong results and guidance. The discussion also centers on a rebound after a steep semiconductor-sector pullback, with dip buyers watching support while others remain cautious about volatility and the earnings reaction.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a sharp AI-neocloud selloff tied to concerns about financing the data-center buildout and whether future returns will justify the spending; traders are debating whether its rebound is a durable recovery or a short-lived bounce. Some argue Nebius is better positioned than more debt-heavy peers, while others remain cautious about funding, cash flow and continued selling pressure.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention after a steep selloff to post-IPO lows, with traders citing staged lockup expirations and insider share sales as added selling pressure alongside a TD Cowen price-target cut. The bearish debate centers on OpenAI customer concentration and the companys ability to scale, while bulls point to its AI-chip technology and argue the shares are oversold.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows is being linked by traders to weakening support for Trump ahead of the midterms, with many voicing bearish views and pointing to Truth Socials limited engagement and the companys weak business fundamentals. A smaller bullish contingent views the selloff as a buying opportunity and cites the planned TAE Technologies merger.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

HPE is drawing attention after a sharp selloff alongside enterprise-hardware peers, following Barclays downgrade and concerns that AI-related revenue gains may reflect higher hardware prices more than accelerating demand. Traders are split between viewing the decline as an overreaction and buying opportunityciting AI-server and networking prospectsand worrying that valuations and growth expectations have run ahead of fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky

ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & KorsinskyPR NewswireNEW YORK, Oct. 13, 2026ArriVent BioPharma shares lost more than half their value after the pivotal Phase 3 FURVENT trial of lead...

AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ArriVent BioPharma, Inc. (ArriVent or the Company) (NASDAQ: AVBP) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...

AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma

AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharmaPR NewswireNEW YORK, Oct. 7, 2026AVBP was down 56.7...

ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)

ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP) ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)PR NewswireNEW YORK, Oct. 6...

ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low

ArriVent BioPharma announced its Phase 3 lung cancer trial for firmonertinib missed the primary endpoint but showed secondary benefits.read more...

AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’

Equity

ArriVent BioPharma’s experimental lung cancer treatment failed to meet its primary endpoint in a Phase 3 trial.

ArriVent BioPharma (NASDAQ:AVBP) Upgraded at Truist Financial

Truist Financial upgraded ArriVent BioPharma to a "strong-buy" rating in a research note on Monday...

ArriVent BioPharma (AVBP) Expected to Announce Quarterly Earnings on Monday

ArriVent BioPharma (NASDAQ:AVBP) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-arrivent-biopharma-inc-stock...

Noteworthy Thursday Option Activity: AVBP, VIAV, ASTS

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in ArriVent Biopharma Inc (Symbol: AVBP), where a total volume of 4,042 contracts has been traded thus far today, a contract volume which is representative of appro...

FY2026 Earnings Estimate for AVBP Issued By Lifesci Capital

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Equities researchers at Lifesci Capital dropped their FY2026 earnings per share estimates for ArriVent BioPharma in a report released on Monday, April 27th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings of...

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.

ArriVent BioPharma Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>Firmonertinib did not significantly improve progression-free survival compared with chemotherapy.</li><li>The 240 mg dose produced a 60% confirmed response rate, compared to 33% for chemotherapy.</li><li>The company continues to test the drug in a separate Phase 3 trial</li></ul>Shares of ArriVent BioPharma (AVBP) crashed over 48% to a record low on Tuesday after the biotech company said its experimental lung-cancer treatment failed to meet the main goal of a Phase 3 trial.<a href="https://stocktwits.com/symbol/AVBP">AVBP stock</a> also clocked its biggest ever single-day slump.<h2 class="st-heading-2">Firmonertinib Misses Main Goal</h2>The Phase 3 Furvent study tested Firmonertinib as a first-line treatment for patients with advanced non-small cell lung cancer with mutations, a difficult-to-treat form of the disease. The study’s primary endpoint was progression-free survival, or how long patients lived without their cancer worsening, as assessed by an independent review committee.Patients receiving the higher 240 mg dose had median progression-free survival of 11 months, compared with 9.5 months for chemotherapy. However, the result did not reach statistical significance.However, the 240 mg dose produced a 60% confirmed response rate, compared to 33% for chemotherapy.<h2 class="st-heading-2">Firmonertinib To Be Developed In A Different Trial</h2>Firmonertinib has already received Breakthrough Therapy and Orphan Drug designations in the U.S. and is approved in China for several&nbsp;EGFR-mutant lung cancer indications.The company said it is reviewing the full Furvent dataset before deciding the program’s next steps. The company continues to test the drug in a separate Phase 3 trial.<h2 class="st-heading-2">What’s In The Pipeline?</h2>Beyond lung cancer, ArriVent is developing ARR-217 for gastrointestinal cancers. The drug is currently in Phase 1b dose optimization. It is also developing ARR-002, an experimental therapy for ovarian and endometrial cancers that received U.S. Food and Drug Administration (FDA) clearance to begin human testing in May.ArriVent ended June with $373.1 million in cash and investments, up from $312.8 million at the end of 2025. Management said the balance should be sufficient to fund operations through 2028.<h2 class="st-heading-2">Retail Turns Extremely Bullish</h2>Despite the slump, retail sentiment surrounding AVBP on Stocktwits turned ‘extremely bullish’ from ‘bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/AVBP_9ca983d356.png" alt="AVBP.png">One user said the stock was “way undervalued.”<stembedurl>https://stocktwits.com/Nitish_mahajan2/message/665857233</stembedurl>Another user expects the stock to climb to at least $17 by the end of the session. It is currently trading at around $14.8.<stembedurl>https://stocktwits.com/Fa07/message/665859832</stembedurl>The stock is down around 30% so far this year.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/spcx-stock-rallies-20-in-three-sessions-why-does-goldman-see-another-30-upside/cZDtaf1RBlJ">SPCX Stock Rallies 20% In Three Sessions – Why Does Goldman See Another 30% Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a chart depicting stock market crash, is displayed on a mobile phone screen in Ankara, Turkiye on August 5, 2024. (Photo by Osmancan Gurdogan/Anadolu via Getty Images)

SPDR S&P Biotech ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$17.94
Prev Close	$16.66
Open	$16.82
Dividend Yield	0.00%
50-Day Moving Average	$27.08
Beta	0.91
Avg. Volume	637,138.80
PE Ratio	-4.87

52-Week High	$35.83
52-Week Low	$11.36
Market Capitalization	$821.47M
EPS (Annual)	-$4.32
Price to Book	2.36
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

AVBP Fundamentals